Brief: GT Biopharma Announces FDA Clearance Of Investigational New Drug Application For GTB-3650, An NK Cell Engager For Treatment Of CD33+ Leukemia

GT Biopharma

27/06/2024 15:02

June 27 (Reuters) - GT Biopharma Inc  GTBP.O :
    * GT BIOPHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW DRUG
(IND) APPLICATION FOR GTB-3650, AN NK CELL ENGAGER FOR TREATMENT
OF CD33+ LEUKEMIA
    * GT BIOPHARMA INC: GTB-3650 PHASE 1 TRIAL INITIATION
EXPECTED IN
H2 2024
    * GT BIOPHARMA INC: GTB-5550 TRIKE IND SUBMISSION FOR
TREATMENT OF
B7H3 POSITIVE SOLID TUMORS EXPECTED IN Q1 2025
    * GT BIOPHARMA INC: GTB-5550 PHASE 1 DOSE ESCALATION BASKET
TRIAL
INITIATION EXPECTED IN 2025
    * GT BIOPHARMA INC: GTB-3650 PHASE 1 INITIAL CLINICAL DATA
EXPECTED IN H1 2025

Source text for Eikon:  ID:nGNX2Vjnk7 
Further company coverage:  GTBP.O 

 ((Reuters.Briefs@thomsonreuters.com;))